Targeting of VPS18 by the lysosomotropic agent RDN reverses TFE3-mediated drug resistance

Signal Transduct Target Ther. 2021 Jun 7;6(1):224. doi: 10.1038/s41392-021-00547-x.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics
  • Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / metabolism*
  • Drug Resistance, Neoplasm / drug effects*
  • Drug Resistance, Neoplasm / genetics
  • Humans
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / metabolism*
  • Neoplasms / drug therapy
  • Neoplasms / genetics
  • Neoplasms / metabolism*
  • Neoplasms / pathology
  • PC-3 Cells
  • Phenyl Ethers* / chemistry
  • Phenyl Ethers* / pharmacology
  • Stilbenes* / chemistry
  • Stilbenes* / pharmacology
  • Vesicular Transport Proteins / genetics
  • Vesicular Transport Proteins / metabolism*

Substances

  • Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
  • Neoplasm Proteins
  • Phenyl Ethers
  • Stilbenes
  • TFE3 protein, human
  • VPS18 protein, human
  • Vesicular Transport Proteins
  • riccardin D